Antibodies to tumor necrosis factor-α in the treatment of Crohn's disease

Steven J. Brown, Maria T Abreu

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Crohn's disease is characterized by acute and chronic intestinal inflammation, and can involve any part of the gastrointestinal tract. The most frequently involved areas of the intestine (the terminal ileum and colon) have higher bacterial loads than the rest of the intestine, suggesting a role for a dysregulated immune response to luminal bacteria. Research into the pathogenesis of Crohn's disease using animal models supports a role for Th1-mediated immune responses, and inhibition of the generation of a Th1 response is known to prevent disease. Based on these observations, antitumor necrosis factor-α (anti-TNFα) therapies have been used to treat patients with Crohn's disease and more recently with ulcerative colitis. Certain anti-TNFα therapies, such as infliximab, have resulted in dramatic clinical responses in patients with Crohn 's disease. Other therapies such as etanercept, however, have not been effective. In this review we will discuss the different strategies that have been employed to inhibit TNFα and their relative merits. We will also address factors that predict response to therapy such as concurrent immunomodulators, high C-reactive protein expression, and polymorphisms in the Fcγ receptor.

Original languageEnglish
Pages (from-to)160-168
Number of pages9
JournalCurrent Opinion in Drug Discovery and Development
Volume8
Issue number2
StatePublished - Mar 1 2005
Externally publishedYes

Fingerprint

Crohn Disease
Tumor Necrosis Factor-alpha
Antibodies
Intestines
Necrosis
Fc Receptors
Bacterial Load
Immunologic Factors
Therapeutics
Ulcerative Colitis
Ileum
C-Reactive Protein
Gastrointestinal Tract
Colon
Animal Models
Inflammation
Bacteria
Research

Keywords

  • Crohn's disease
  • Etanercept
  • Gastrointestinal
  • Infliximab
  • TNFα

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Antibodies to tumor necrosis factor-α in the treatment of Crohn's disease. / Brown, Steven J.; Abreu, Maria T.

In: Current Opinion in Drug Discovery and Development, Vol. 8, No. 2, 01.03.2005, p. 160-168.

Research output: Contribution to journalArticle

@article{bfb5be01ab25498bb530a2b9a7c33e24,
title = "Antibodies to tumor necrosis factor-α in the treatment of Crohn's disease",
abstract = "Crohn's disease is characterized by acute and chronic intestinal inflammation, and can involve any part of the gastrointestinal tract. The most frequently involved areas of the intestine (the terminal ileum and colon) have higher bacterial loads than the rest of the intestine, suggesting a role for a dysregulated immune response to luminal bacteria. Research into the pathogenesis of Crohn's disease using animal models supports a role for Th1-mediated immune responses, and inhibition of the generation of a Th1 response is known to prevent disease. Based on these observations, antitumor necrosis factor-α (anti-TNFα) therapies have been used to treat patients with Crohn's disease and more recently with ulcerative colitis. Certain anti-TNFα therapies, such as infliximab, have resulted in dramatic clinical responses in patients with Crohn 's disease. Other therapies such as etanercept, however, have not been effective. In this review we will discuss the different strategies that have been employed to inhibit TNFα and their relative merits. We will also address factors that predict response to therapy such as concurrent immunomodulators, high C-reactive protein expression, and polymorphisms in the Fcγ receptor.",
keywords = "Crohn's disease, Etanercept, Gastrointestinal, Infliximab, TNFα",
author = "Brown, {Steven J.} and Abreu, {Maria T}",
year = "2005",
month = "3",
day = "1",
language = "English",
volume = "8",
pages = "160--168",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "2",

}

TY - JOUR

T1 - Antibodies to tumor necrosis factor-α in the treatment of Crohn's disease

AU - Brown, Steven J.

AU - Abreu, Maria T

PY - 2005/3/1

Y1 - 2005/3/1

N2 - Crohn's disease is characterized by acute and chronic intestinal inflammation, and can involve any part of the gastrointestinal tract. The most frequently involved areas of the intestine (the terminal ileum and colon) have higher bacterial loads than the rest of the intestine, suggesting a role for a dysregulated immune response to luminal bacteria. Research into the pathogenesis of Crohn's disease using animal models supports a role for Th1-mediated immune responses, and inhibition of the generation of a Th1 response is known to prevent disease. Based on these observations, antitumor necrosis factor-α (anti-TNFα) therapies have been used to treat patients with Crohn's disease and more recently with ulcerative colitis. Certain anti-TNFα therapies, such as infliximab, have resulted in dramatic clinical responses in patients with Crohn 's disease. Other therapies such as etanercept, however, have not been effective. In this review we will discuss the different strategies that have been employed to inhibit TNFα and their relative merits. We will also address factors that predict response to therapy such as concurrent immunomodulators, high C-reactive protein expression, and polymorphisms in the Fcγ receptor.

AB - Crohn's disease is characterized by acute and chronic intestinal inflammation, and can involve any part of the gastrointestinal tract. The most frequently involved areas of the intestine (the terminal ileum and colon) have higher bacterial loads than the rest of the intestine, suggesting a role for a dysregulated immune response to luminal bacteria. Research into the pathogenesis of Crohn's disease using animal models supports a role for Th1-mediated immune responses, and inhibition of the generation of a Th1 response is known to prevent disease. Based on these observations, antitumor necrosis factor-α (anti-TNFα) therapies have been used to treat patients with Crohn's disease and more recently with ulcerative colitis. Certain anti-TNFα therapies, such as infliximab, have resulted in dramatic clinical responses in patients with Crohn 's disease. Other therapies such as etanercept, however, have not been effective. In this review we will discuss the different strategies that have been employed to inhibit TNFα and their relative merits. We will also address factors that predict response to therapy such as concurrent immunomodulators, high C-reactive protein expression, and polymorphisms in the Fcγ receptor.

KW - Crohn's disease

KW - Etanercept

KW - Gastrointestinal

KW - Infliximab

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=14844311937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844311937&partnerID=8YFLogxK

M3 - Article

C2 - 15782540

AN - SCOPUS:14844311937

VL - 8

SP - 160

EP - 168

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 2

ER -